Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 219 participants.
Also called NCT03014479
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 219 participants
- Sponsor
- Registry
-
NCT03014479 -
U1111-1189-9256
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT03014479. Randomized; no masking; primary purpose treatment. Start 2017-02-18 (actual); primary completion 2017-10-21 (actual). Results posted on 2019-02-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus
- Acronym
- TRENDS
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Trelagliptin
- Intervention (Drug)
- Daily DPP-4 inhibitor
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct03014479- Content hash
34cb303a3a1152096556f9db1ef365f78f470591a12e3340cef876262ea07317